Thermo Fisher Scientific, Inc.

DUBLIN--( BUSINESS WIRE )--The "Bioprocess Optimization and Digital Bio-manufacturing: Global Markets" report has been added to ResearchAndMarkets.com's offering. The Global Bioprocess Optimization and Digital Bio-manufacturing Market was valued at USD 24.3 Billion in 2024, and is expected to reach USD 39.6 Billion by 2029, rising at a CAGR of 10.20%. The report provides a comprehensive analysis of the bioprocess optimization and digital biomanufacturing market in a global context, including market forecasts and sales through the year 2029. Segmentation based on technology type includes manufacturing technologies (chromatography-based separation and purification, filtration, bioreactors, centrifugation), analytical and process control technologies (spectrophotometry, automation and industrial process control technologies, analytical chromatography, sensors and probes), and software (Industrial control and automation software, bioprocess optimization and data analytics software). Segmentation based on application includes biomanufacturing process automation and control, flexible manufacturing, bioprocess optimization and process analytics, and others. By molecule type the market is segmented into monoclonal antibodies, vaccines, therapeutic proteins and peptides, and cell and gene therapies. The regional markets covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The report discusses the critical issues impacting the adoption of digital biomanufacturing in pharmaceuticals, as well as emerging trends in digital biomanufacturing technologies. It also features new developments and new product launches in the global market. The report provides comprehensive profiles of market players in the industry. The report also covers mergers and acquisitions and any other collaborations or partnerships that occurred during the evaluation period of this report and which are expected to shape the industry. Report Scope 69 data tables and 61 additional tables Analyses of trends in the global market for bioprocess optimization and digital bio-manufacturing, with market revenue data for 2021-2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029 Estimates of the market size and revenue growth prospects of the global market, along with a market share analysis by technology, application, drug molecule type and region Facts and figures pertaining to the market dynamics, technical advances, regulations and the impact of macroeconomic factors Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses Analysis of patents, emerging trends, and new developments Analysis of the industry structure, including companies' market shares, strategic alliances, M&A activity and a venture funding outlook Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies Profiles of the market leaders, including Agilent Technologies Inc., Thermo Fisher Scientific Inc., Danaher Corp., and Sartorius AG. Key Attributes: Report Attribute Details No. of Pages 180 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $24.3 Billion Forecasted Market Value (USD) by 2029 $39.6 Billion Compound Annual Growth Rate 10.2% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Technology Background Biologics Manufacturing Process Upstream Processing Cell Harvesting and Clarification Downstream Processing Bioprocess Optimization Industry 4.0 - Digital Biomanufacturing Chapter 3 Market Dynamics Market Drivers Growing Aging Population Increasing Prevalence of Chronic Diseases Unprecedented Rise in Demand for Biopharmaceuticals Growing Number of Product Launches Increasing Number of Contract Manufacturing Organizations (CMOs) Market Restraints Lack of Skilled Labor High Cost of Equipment Unharmonized Smart Manufacturing Standards Market Opportunities Favorable Government Programs Advances in Sensor Technology Process Analytical Technology Initiatives Market Challenges Technical Issues and the Threat of Cyberattacks Regulatory Landscape Good Automation Manufacturing Practices (GAMP) Instrumentation, Systems, and Automation (ISA) Society-88 and 95 Standards Chapter 4 Emerging Technologies and Developments Emerging Trends and Technologies Continuous Bioprocessing Continuous Cell Retention Technologies Continuous Chromatography Single-Use Technologies Chapter 5 Market Segmentation Analysis Market Analysis by Technology Manufacturing Technologies Analytical and Process Control Technologies Software Market Analysis by Application Biomanufacturing Process Automation and Control Flexible Manufacturing Bioprocess Optimization and Process Analytics Other Applications Market Analysis by Molecule Type Monoclonal Antibodies (mAbs) Therapeutic Proteins and Peptides Vaccines Cell and Gene Therapies Market Analysis by Region Chapter 6 Competitive Intelligence Ranking of Leading Players Key Strategies Adopted by Players Collaborations and Partnerships Expansion Acquisitions New Product Launches Chapter 7 Sustainability in the Bioprocess Optimization and Digital Biomanufacturing Market: An ESG Perspective ESG Practices in the Industry Companies' ESG Risk Ratings Company Profiles Agilent Technologies Agilitech Bio-Rad Laboratories Bruker Clean Biologics Danaher Emerson Electric Eppendorf Korber Merck Sartorius Shimadzu Thermo Fisher Scientific Univercells Technologies Waters For more information about this report visit https://www.researchandmarkets.com/r/vlkua2 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN--( BUSINESS WIRE )--The "Single-use Technologies for Biopharmaceuticals Market" report has been added to ResearchAndMarkets.com's offering. The Single-use Technologies for Biopharmaceuticals was valued at USD 6.5 billion in 2024, and is projected to reach USD 11.2 billion by 2029, rising at a CAGR of 11.60%. This report summarizes the single-use technologies market, including a market snapshot and company profiles of key players. It provides a comprehensive market breakdown with in-depth information regarding each segment. The overview section of the report describes market trends and dynamics, including drivers, challenges and opportunities for the market. It provides information on emerging technologies and developments in the industry. It analyzes critical market players' financials, product portfolios and recent activities. The report analyzes and makes projections for each market and its applications, along with forecasts for the next five years. The report also features profiles of leading companies in the biopharmaceutical single-use technologies industry, including Sartorius AG, Danaher Corp, Merck KGaA and Thermo Fisher Scientific Inc. Key Findings The increasing demand for personalized medicine and the growing number of single-use product launches in bioprocessing operations drive the market's growth. The integration challenges and regulatory validation requirements challenge the market's growth. This report segments the global market by technology type, component type, application, end user and region. By technology type, single-use bioreactors held the largest market share in 2023, and this segment is expected to grow at a CAGR of 12.3% during the forecast period. In terms of application, the monoclonal antibodies segment is forecast to grow at a CAGR of 11.3% during the forecast period. This segment accounted for 32.7% of the market in 2023, reaching a value of $3.6 billion through 2029. The bioprocess containers segment accounted for 17.6% of the market by component type in 2023. It is expected to grow at a CAGR of 10.1% during the forecast period, reaching a value of $1.8 billion by the end of 2029. North America held the largest regional market share with 31.5% in 2023. Increasing research and development (R&D) activities in cell and gene therapies and the significant regional presence of single use systems companies are responsible for the large share. The report includes: 220 data tables and 59 additional tables An analysis of the global markets for single-use technologies for biopharmaceutical manufacturing Analyses of global market trends, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029 Estimates of the size and revenue prospects of the global market, along with a market share analysis by technology, single-use component, application, end user, and region/country A look at recent technical advances in different sole-use technologies and bioreactors and the extent of adoption by commercial customers and regulatory authorities Facts and figures pertaining to the market dynamics, technical advances, regulations, and the impact of region- and industry-specific macroeconomic variables A Porter's Five Forces model, and global supply chain and PESTLE analyses Patent activity and key patent grants/publications, along with an analysis of the impact of new developments in sole-use technologies and bioreactors for pharmaceuticals Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies Analysis of the industry structure, including company market shares, strategic alliances, M&A activity and a venture funding outlook Profiles of market leaders, including: Danaher Corp, Thermo Fisher Scientific Inc., Sartorius AG and Merck KGaA. Key Attributes: Report Attribute Details No. of Pages 207 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $6.5 Billion Forecasted Market Value (USD) by 2029 $11.2 Billion Compound Annual Growth Rate 11.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Insights Chapter 2 Market Overview Historical Analysis: The Foundation for Single-Use Technology Raw Materials Used in Single-Use Technologies Polyamide Polycarbonate Polyethylene Polyethersulfone Polypropylene Polytetrafluoroethylene Polyvinyl Chloride Cellulose Acetate Ethylene Vinyl Acetate Single-Use Technology Versus Traditional Reusable Technology Biologics Process Development Pathway and Application of Single-Use Technologies Upstream Processing Cell Harvesting and Clarification Downstream Processing Chapter 3 Market Dynamics Market Dynamics Snapshot Market Drivers Increasing Product Launches Growing Demand for Personalized Medicine Market Challenges and Restraints Stringent Regulations and Validation Requirements Disposal of Plastic Waste Integration Challenges Market Opportunities Growing Adoption for Monoclonal Antibodies Manufacturing Single-Use Systems in Downstream Operations Chapter 4 Emerging Technologies and Developments Introduction Real-Time Monitoring of Operations Miniaturization of Bioreactors Integration of Automation and Robotics Integrated Continuous Bioprocessing Chapter 5 Market Segmentation Analysis Segmentation Breakdown Market Analysis by Technology Single-Use Bioreactors Mixing, Storage and Filling Systems Filtration Systems Control Systems Freeze and Thaw Systems Chromatography Systems Centrifugal Pumps Isolators Market Analysis by Component Bioprocess Containers Sampling Systems Single-Use Sensors Transfer Systems Media Bags Filter Cartridges Tubing Connectors Other Single-Use Products Market Analysis by Application Monoclonal Antibodies Vaccines Stem Cell and Other Cell Therapies Blood Derivatives Gene Therapy Recombinant Proteins Polyclonal Antibodies Market Analysis by End User Biopharmaceutical Companies and Contract Manufacturers Research Institutes and Academia Pathology Laboratories Geographic Breakdown Market Analysis by Region North America Europe Asia-Pacific Rest of the World Chapter 6 Competitive Intelligence Competitive Landscape Partnerships Acquisitions Facility Expansions Patent Analysis Chapter 7 Sustainability in the Single-Use Technologies for Biopharmaceuticals Market Sustainability in the Biopharmaceutical Single-Use Technologies Industry Understanding Environmental, Social and Governance Data Environmental Performance Social Performance Governance Performance Concluding Remarks Chapter 8 Appendix Methodology Sources Abbreviations Company Profiles Aber Instruments Ltd. Adolf Kuhner AG Cellexus Celltainer Corning Inc. Danaher Corp. Distek Inc. Eppendorf SE Getinge Lonza Merck KGaA Sartorius AG Thermo Fisher Scientific Inc. For more information about this report visit https://www.researchandmarkets.com/r/jf476 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Lyndra’s drug delivery platform optimises the delivery of oral medicines. Credit: Stock-Asso/Shutterstock. Lyndra Therapeutics and Thermo Fisher Scientific have entered a strategic partnership to develop Lyndra’s long-acting oral therapies for conditions such as schizophrenia and bipolar disorder. Lyndra will utilise Thermo Fisher’s worldwide clinical research and commercial manufacturing services for its therapies, including its lead investigational product, oral weekly risperidone (LYN-005). LYN-005 recently achieved its primary endpoint in the pivotal Phase III STARLYNG-1 trial, showcasing its efficacy against daily risperdal. The partnership will leverage Thermo Fisher’s accelerator drug development services, which offer a suite of manufacturing, clinical research and clinical supply chain services. The services are tailored to support biotech and pharmaceutical companies from pre-clinical stages to commercialisation. Lyndra aims to harness Thermo Fisher’s pharmaceutical manufacturing capabilities in Cincinnati in the US state of Ohio. This includes the commercial line for Lyndra’s LYNX drug delivery platform, which will facilitate the manufacturing of commercial materials at scale. The platform is tailored to enhance clinical outcomes by optimising the delivery of oral medicines. The technology underpinning the LYNX platform was developed in the Traverso and Langer Laboratories, from which Lyndra has an exclusive technology licence. The partnership also opens opportunities for other pharmaceutical partners interested in creating long-acting oral therapies using LYNX platform technology. Lyndra Therapeutics global product development president and chief medical officer Dr Richard Scranton stated: “Lyndra’s clinical research and manufacturing collaboration with Thermo Fisher is a critical step in our mission to transform how patients take medicine, providing the capabilities and scale to bring long-acting oral therapies to broad markets. “Thermo Fisher will be part of our ecosystem of best-in-class partners as we execute our go-to-market strategy, allowing Lyndra to focus on what we do best – research and development for innovative long-acting oral therapeutic solutions – while ensuring reliable, scalable manufacturing and clinical trial operations.” In December 2023, Lyndra secured $101m in Series E financing to advance its pipeline of long-lasting oral therapy products.